Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study.
about
KASL clinical practice guidelines: management of hepatitis CNanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virusRecent trends in the treatment of chronic hepatitis CEvaluation of Dual Therapy in Real Life Setting in Treatment-Naïve Turkish Patients with HCV Infection: A Multicenter, Retrospective StudyIncidence and risk factors of hepatitis C virus infection among human immunodeficiency virus (HIV) patients in a large HIV clinic in South Korea.Clinical Characteristics and Treatment Outcome of Peginterferon Plus Ribavirin in Patients Infected with Genotype 6 Hepatitis C Virus in Korea: A Multicenter Study.Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study.Urgency to treat patients with chronic hepatitis C in Asia.Efficacy of vitamin D supplementation in combination with conventional antiviral therapy in patients with chronic hepatitis C infection: a meta-analysis of randomised controlled trials.Current status of hepatitis C virus infection and countermeasures in South Korea.Hepatitis C viral kinetics as a determinant of stopping pegylated interferon and ribavirin in genotype 1 infection.A nationwide seroepidemiology of hepatitis C virus infection in South Korea.Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?KASL clinical practice guidelines: management of hepatitis C.2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
P2860
Q26752471-50E953D4-B53F-4F5D-BEDA-5A65EB66B864Q33559298-638CAA62-5247-4AA5-8B55-0397F073B8D8Q35833159-A64D96C7-9574-4DCE-ABC7-D862C1CDA669Q35890619-3A143B85-8375-4709-A934-14A4E49A33D4Q36618416-7761E1D8-3B49-421E-8C1F-BD6FA53B382CQ37081478-018FDD23-9874-48C6-9D84-6856CF51000FQ37696052-0C4B660D-1970-4E0D-8B8C-0084A559C0C9Q38433971-A75A2589-4D9D-49E4-B137-30D463B118FDQ38929826-DAB9E7C7-8022-46A0-B59B-8AA95A84CF81Q39049155-AB6A7E3D-2C5F-4C9A-8FD3-DBF8C9F805A6Q40073734-6A874F54-D164-42F1-B74E-2310B80D7DCEQ42342099-57250014-3200-470A-87BA-35013CFE41A4Q42752054-B61FD8A3-64DD-43DD-ADC1-E617AD970E1FQ42988684-74CCFFF0-EC18-4BDC-AC4A-A0E757FB7802Q43199205-7E4063D8-288C-4448-93DD-FA7FC11D8206Q51836024-53B6DBA8-0FB5-4E76-A469-80FAA818B66AQ58788714-7C1F4449-9495-4C06-AD62-A40C829842A4
P2860
Efficacy and tolerability of peginterferon alpha plus ribavirin in the routine daily treatment of chronic hepatitis C patients in Korea: a multi-center, retrospective observational study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Efficacy and tolerability of p ...... ospective observational study.
@ast
Efficacy and tolerability of p ...... ospective observational study.
@en
type
label
Efficacy and tolerability of p ...... ospective observational study.
@ast
Efficacy and tolerability of p ...... ospective observational study.
@en
prefLabel
Efficacy and tolerability of p ...... ospective observational study.
@ast
Efficacy and tolerability of p ...... ospective observational study.
@en
P2093
P2860
P356
P1433
P1476
Efficacy and tolerability of p ...... ospective observational study.
@en
P2093
Choong Kee Park
Chun Kyon Lee
Hyung Joon Yim
Jae Youn Cheong
Jeong Won Jang
Jin Mo Yang
Jin Woo Lee
Joo Hyun Shon
Ju Hyun Kim
June Sung Lee
P2860
P304
P356
10.5009/GNL.2012.6.1.98
P577
2012-01-12T00:00:00Z